Maternal exposure to increased synthetic glucocorticoids (GC) during pregnancy is known to disturb fetal development and increase the risk of long-term disease. Maternal exposure to elevated levels of natural GC is likely to be common yet is relatively understudied. The placenta plays an important role in regulating fetal exposure to maternal GC but is itself vulnerable to maternal insults. This study uses a mouse model of maternal corticosterone (Cort) exposure to investigate its effects on the developing placenta. Mice were treated with Cort (33 g/kg⅐h) for 60 h starting at embryonic d 12.5 (E12.5) before collection of placentas at E14.5 and E17.5. Although Cort exposure did not affect fetal size, placentas of male fetuses were larger at E17.5 in association with changes in placental Igf2. This increase in size was associated with an increase in placental thickness and an increase in placental junctional zone volume. Placentas from female fetuses were of normal size and had no changes in growth factor mRNA levels. The expression of the protective enzyme 11␤-hydroxysteroid dehydrogenase type 2 was increased at E14.5 but was decreased in males at E17.5. In contrast, the expression of Nr3c1 (which encodes the GC receptor) was increased during the Cort exposure and remained elevated at E17.5 in the placentas of male fetuses. Our study has shown that maternal Cort exposure infers a sex-specific alteration to normal placental growth and growth factor expression, thus further adding to our understanding of the mechanisms of male dominance of programmed disease. (Endocrinology 153: 5500 -5511, 2012)
T he development of a healthy fetus is dependent on an intrauterine environment free from adverse conditions. It has been well documented that excessive maternal glucocorticoid (GC) exposure results in high fetal GC exposure and subsequently results in altered fetal development and long-term health deficits (1) . This research has largely focused on the consequences of fetal exposure to synthetic GC, commonly given to women at risk of preterm delivery to accelerate fetal lung surfactant development to ensure survival of the preterm infant (2) . However, little research has investigated the effects of excess maternal exposure to the natural GC [cortisol in humans and corticosterone (Cort) in rodents], which is surprising considering exposure to stress during pregnancy is likely to be common. Cortisol can be produced at any time of gestation, and levels have been shown to be elevated in pregnant women who have experienced stressful life events (3) and in women suffering from depression (4). Such events have been shown to likewise increase infant cortisol levels (5) . With the incidence of prenatal depression estimated to be anywhere from 8 -48% (6) , large numbers of women are potentially exposed to situations in which cortisol levels are sufficiently high as to negatively impact fetal development.
Maternal exposure to elevated Cort during pregnancy is not often considered detrimental to fetal development largely because the fetus is thought to be protected from GC by the placental GC barrier. The main constituent of this barrier, the enzyme 11␤-hydroxysteroid dehydrogenase type 2 (11␤-HSD2, encoded by the gene Hsd11b2), converts active cortisol/Cort into their inactive metabolites but only poorly metabolizes many synthetic GC (7) .
As such, cortisol levels have been shown to be up to 10-fold higher in maternal blood compared with fetal blood depending on fetal age (8) . However, when cortisol/Cort levels are sufficiently high, this barrier is ineffective (9) , allowing the natural GC into the fetal circulation. Furthermore, although the fetus is at least partially protected from elevations in natural GC in the mother, the developing placenta is exposed to levels of GC equal to that of the maternal circulation, making it vulnerable to GC exposure. Although synthetic GC bind very specifically to the GC receptor (GR) to exert a wide range of responses, Cort can bind with not only the GR but also the mineralocorticoid receptor. Thus, Cort may have different effects on placental development and should be studied as a separate programming agent from synthetic GC.
We and others have reported that short-term exposure of the rodent to the synthetic GC dexamethasone results in impaired placental development/function (10 -13) . Because the placenta functions largely to facilitate the exchange of nutrients and waste between maternal and fetal blood supplies, disruption of placental growth or function may result in fetal growth restriction and impaired fetal development. A number of growth factors have been shown to be vital for placental growth with IGF and vascular endothelial growth factors (VEGF) being particularly important. Administration of synthetic GC to rodents has been shown to alter placental weight in association with changes in the expression of junctional zone IGF-II (10) and labyrinth VEGFA (11) . Interestingly, many of these changes were dependent upon the sex of the fetus from which the placenta was obtained. Although basal fetal and placental size as well as protein and mRNA expression are often not different between males and females, studies have shown clear sex-specific responses to synthetic GC in animal models (12, 13) . Human studies have likewise shown sex-specific placental responses to GC (14, 15) .
The overall aim of the current study was to investigate the effects of maternal exposure to Cort on the growth of the developing placenta in the mouse and to explore some of the mechanisms that may mediate these effects. In addition, we aimed to examine whether these effects were dependent upon fetal sex and to compare and contrast results with those we have recently reported after exposure to dexamethasone (12) . We hypothesized that Cort would increase placental 11␤-HSD2 expression, but not sufficiently as to completely protect the developing fetus from Cort exposure. Furthermore, we suggest excessive Cort exposure would negatively affect placental size in association with changes to placental structure and growth factor expression in a sex-specific manner. The current study provides an important link between epidemiological data showing how altered placental size, shape, and structure can increase incidence of adult disease and the common perturbation of stress during pregnancy.
Materials and Methods

Animal treatment
All experiments were approved by The University of Queensland animal ethics committee. Virgin C57BL/6 mice were time mated over a 3-h period with pregnancy being confirmed by the presence of seminal plugs and recorded as embryonic d 0.5 (E0.5). At E12.5, dams were anesthetized for the sc implantation of an osmotic pump (model 1003D, with 100-l capacity and 1-l/h delivery rate; Alzet, Durect Corp., Cupertino, CA) as described previously (13) . Pumps were filled to capacity with Cort (27840; Sigma-Aldrich, Castle Hill, New South Wales, Australia) and released their contents at a rate of 33 g/kg⅐h. Pumps were primed for a 60-h infusion of Cort (E12.5-E15). Although we have previously used a saline control group when examining the effects of dexamethasone, the control group felt to be most appropriate for this study was an untreated (Untr) group not exposed to the stress resulting from anesthesia and surgery. Dams were killed by cervical dislocation at E14.5 (Untr n ϭ 7; Cort n ϭ 7) or at E17.5 (Untr n ϭ 10; Cort n ϭ 8) and placentas and fetuses collected. At E14.5, maternal adrenal glands were collected for mRNA analysis and blood collected for measurements of plasma Cort. Cort was measured by a RIA (07120102; MP Biomedicals, Solon, OH) following the manufacturer's procedures. The intraassay coefficient of variation was 3.3%.
Tissue collection and measurements
Placentas were weighed to the nearest 0.1 g and the width (length of minor axis), length (length of major axis), and depth (maximal thickness after removal of decidua) measured using digital calipers with 0.01-mm resolution. Placentas were frozen in liquid nitrogen or fixed in 4% paraformaldehyde. A subset of placentas (one male and one female from each litter) was taken for calculating placental dry weights. This was achieved by dehydrating placentas at 37 C and weighing them until weight no longer changed.
Fetus sex identification
Fetal weight was recorded and tails removed and incubated in lysis buffer with proteinase K overnight at 55 C. The proteinase K was deactivated by heating at 95 C for 10 min and samples vortexed. Real-time PCR was performed for Sry (sex-determining region Y, Mm00441712_s1).
RNA extraction and real-time PCR
RNA was extracted from maternal adrenal glands and placental quarters using the RNeasy mini kit (QIAGEN, Doncaster, Victoria, Australia). RNA was treated with deoxyribonuclease 1, and 1 g was reverse transcribed in a 50-l reaction (13) . Steroidogenic mRNA levels were measured using Assays-on-Demand primer/probe sets (Applied Biosystems, Foster City, CA) for Star (steroidogenic acute regulatory protein, Mm00441558_m1) and Cyp11b1 (cytochrome P450, family 11, subfamily B, polypeptide 1, Mm01204952_m1). Placental mRNA levels were determined using the following assays: Hsd11b2 (Mm00492541_g1), Nr3c1 (nuclear receptor subfamily 3, group C, member 1, Mm00433832_m1), Nr3c2 (nuclear receptor subfamily 3, group C, member 2, Mm01241596_m1), Igf2 (Mm00439565_g1), Vegfa (Mm00437304_m1), Kdr (kinase insert domain receptor, Mm01222431_m1), and Map2k1 (MAPK kinase 1, Mm00435940_m1). Real-time PCR results were analyzed using the delta delta cycle of threshold fluorescence method with Rn18s (18s) as the endogenous control. All groups were compared with the average of the male Untr animal group.
Protein extraction, SDS-PAGE, and Western blotting
Protein was extracted from placentas (n ϭ 6 of each sex, treatment group, and age) as described previously (13) . Equal total protein (12 g per well) was added to 12% polyacrylamide gels and subjected to SDS-PAGE. Protein was transferred to Immobilon FL polyvinylidene difluoride membranes for Western blotting. Anti-VEGFA (Millipore, Billerica, MA; 1:1000, no. 07-1376), anti-HSD11B2 (Abcam, Cambridge, UK; 1:1000, ab80317), and anti-p44/42 MAPK (MAPK1 and -3, 1:2000; no. 4695; Cell Signaling Biotechnology, Danvers, MA) antirabbit antibodies were used, and an antimouse anti-␤-actin (ACTB, 1:5000; A1978; Sigma-Aldrich) antibody was used as a loading control. LI-COR Biosciences (Lincoln, NE) IRDye 680 goat antirabbit and the IRDye 800CW goat antimouse secondary antibodies were then used and the Western blots analyzed using the LI-COR Odyssey infrared imaging system (Millennium Science, Surrey Hills, Victoria, Australia).
Placental volume
Fixed placentas (n ϭ 6 per treatment group) from male and female E17.5 fetuses were cut in half along the short axis, dehydrated, embedded in paraffin, and exhaustively sectioned at a thickness of 7 m on a standard manual rotary microtome. Sections were selected using unbiased random sampling and stained using hematoxylin and eosin, coverslipped, and scanned using the Aperio ScanScope system (Aperio Technologies, Inc., Vista, CA). Digital slides were visualized using associated ImageScope software at ϫ5 magnification and a 2-cm 2 grid overlaid for point counting using the Cavalieri method (16, 17) . Points falling on placental labyrinth or junctional zone were counted and the following formula applied: V ϭ t ϫ s ϫ a (p) ϫ ⌺P, where V is the volume of each placental component, t is the total placental thickness based on total number of sections multiplied by section thickness, S refers to the sampling fraction used, a (p) is the area of the grid associated with each point, and ⌺P refers to the sum of all points. Labyrinth volume, junctional zone volume, and total placental volume was estimated in this manner and corrected for shrinkage associated with paraffin embedding by calculating the shrinkage of 15 red blood cells per placenta compared with the known blood cell size in these mice.
Statistical analysis
Results are represented as the mean Ϯ SEM. Body and placental weights were calculated as litter averages of sexed individuals. Statistical analyses were performed using GraphPad Prism version 5 for Windows. Weights, measurements, and mRNA expression results were analyzed by two-way ANOVA [with P values for treatment (Ptrt) and sex (Psex) being factors] with Bonferroni post hoc testing when appropriate. Western blot results, placental compartment volumes, and the Cort assay were analyzed using Student's t tests between Untr and Cort groups of the same sex.
Results
Maternal plasma Cort levels and adrenal steroidogenic mRNA levels
Cort infusion significantly increased plasma Cort concentrations by approximately 3-fold at E14.5 (P Ͻ 0.05, Fig. 1A. ). The expression of steroid biosynthetic enzymes have been shown to be down-regulated in response to GC exposure in both maternal (18, 19) and fetal adrenal glands (20) . At E14.5, maternal adrenal Cyp11b1 and Star mRNA levels were reduced by approximately 50% after Cort exposure (P Ͻ 0.05, Fig. 1 , B and C). Thus, Cort exposure was sufficiently high as to exert negative feedback on the maternal HPA and suppress, at least partially, endogenous maternal adrenal steroidogenesis. Cort exposure did not impact litter size at either E14.5 or E17.5 or maternal weight gain (data not shown).
FIG. 1. Effects of Cort exposure (black bars)
on maternal plasma Cort levels (A), relative maternal adrenal Cyp11b1 (B) mRNA levels and Star (C) mRNA levels at E14.5 compared with Untr controls (white bars). Data are represented as the mean Ϯ SEM; n ϭ 5-6 dams per group. *, P Ͻ 0.05.
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Fetal body weight, placental weight, and placental measurements At E14.5, fetal body weight ( Fig. 2A ), placental weight ( Fig. 2C) , and placenta to body weight ratio ( Fig. 2E) were not affected in either sex by Cort exposure. At E17.5, fetal body weights were not statistically significantly different (Ptrt ϭ 0.07, Fig. 2B ). At E17.5, placental weight was increased by Cort exposure (Ptrt Ͻ 0.01), with post hoc testing showing that this was due to a significant increase in the weight of placentas from male fetuses exposed to Cort (Fig. 2D ). In accordance with this, the placenta to body weight ratio at E17.5 was significantly increased by Cort exposure (Ptrt Ͻ 0.01) with post hoc analysis showing that the ratio was increased in the male Cort-exposed group (Fig. 2F) . Placental dry weight was unchanged at E14.5; however, at E17.5, placental dry weight was approximately 50% greater in those from Cort-exposed fetuses compared with those from Untr fetuses (Ptrt Ͻ 0.001, Table 1 ).
At E14.5, placental width was not different in animals exposed to Cort compared with Untr controls. However, placental length (Ptrt Ͻ 0.05, Table 1 ) and placental depth (Ptrt Ͻ 0.01, Table 1 ) were increased in animals exposed to Cort. At E17.5, placental length and width were not affected by Cort exposure (Table 1) ; however, placental depth remained increased in animals previously exposed to Cort (Ptrt Ͻ 0.05, Table 1 ).
GR mRNA expression
Nr3c1 (GR) mRNA expression was increased at E14.5 (Ptrt Ͻ 0.01) in placentas from animals exposed to Cort. Furthermore, males had higher expression levels than females (Psex Ͻ 0.05). A significant sex by treatment interaction (Pint Ͻ 0.01) followed by post hoc analysis (P Ͻ 0.001) showed that Nr3c1 mRNA levels were increased by Cort in placentas from male fetuses only (Fig. 3A) . At E17.5, placental Nr3c1 mRNA levels were increased in Cort-exposed animals (Ptrt Ͻ 0.001, Fig. 3B ) with post hoc analysis showing that this increase in expression was again male specific (P Ͻ 0.001). Nr3c2 (mineralocorticoid receptor) mRNA levels were not affected by Cort exposure at either age (data not shown).
Placental GC barrier gene and protein expression
Hsd11b2 mRNA levels were increased by Cort exposure (Ptrt Ͻ 0.05) in placentas from E14.5 fetuses ( Fig  3C) . Similarly, 11␤-HSD2 protein expression was increased at E14.5 in placentas from Cort-exposed female fetuses (P Ͻ 0.05, Fig 3, E and G) ; however, expression was not significantly different between male Untr and male Cort placentas. At E17.5, placental Hsd11b2 mRNA levels were decreased (Ptrt Ͻ 0.05, Fig 3D) . Post hoc analysis showed that Hsd11b2 mRNA levels were decreased in males (P Ͻ 0.05). At E17.5, although 11␤-HSD2 protein expression in the placentas of males was decreased by 25%, this did not reach statistical significance (P ϭ 0.13, Fig 3, F and H) . At E17.5, 11␤-HSD2 protein expression in placentas from female fetuses was not affected by Cort exposure.
Vasculogenesis gene and protein expression
At E14.5 Kdr mRNA levels (also called Vegfr2) were increased in Cortexposed placentas (Ptrt Ͻ 0.01, Fig.  4A ). Post hoc analysis showed that this difference was due to a significant in- crease in Kdr expression in males (P Ͻ 0.05). At E14.5, Vegfa mRNA levels were significantly increased in placentas from fetuses exposed to Cort compared with Untr controls (Ptrt Ͻ 0.05, Fig. 4C ). Placentas from males had higher Vegfa mRNA expression than placentas from females (Psex Ͻ 0.01). In addition, there was a sex by treatment interaction (Pint Ͻ 0.01). Post hoc analysis showed that Vegfa was increased in Cort-exposed placentas from male fetuses only (P Ͻ 0.01). VEGFA protein expression was decreased in males at E14.5 (P Ͻ 0.01, Fig. 4 , E and G) but not females. At E17.5, Kdr expression was not affected by Cort exposure (Fig. 4B) . Vegfa mRNA levels were significantly decreased in placentas exposed to Cort compared with Untr controls (Ptrt Ͻ 0.05, Fig. 4D ). In addition, a sex by treatment interaction (Pint Ͻ 0.05) and post hoc analysis (P Ͻ 0.05) showed that this decrease in Vegfa expression occurred in placentas from male fetuses exposed to Cort only. VEGFA protein expression at E17.5 was increased in males (P Ͻ 0.05, Fig. 4, F and H) but not females.
Growth factor gene expression
At E14.5, Igf2 mRNA levels were significantly increased in placentas exposed to Cort compared with Untr controls (Ptrt Ͻ 0.001, Fig. 5A) . A sex by treatment interaction (Pint Ͻ 0.05) and post hoc analysis (P Ͻ 0.001) showed that this increase in Igf2 mRNA occurred in males only. At E17.5, Igf2 mRNA levels were decreased in placentas from Cort-exposed fetuses (Ptrt Ͻ 0.01, Fig. 5B ). Post hoc analysis showed Igf2 mRNA levels were decreased in placentas from male Cort-exposed fetuses (P Ͻ 0.05).
Map2k1 was significantly increased in placentas of fetuses prenatally exposed to Cort at E14.5 (Ptrt Ͻ 0.05, Fig.   5C ). Post hoc analysis showed that the increase in Map2k1 expression at E14.5 was caused by an increase in mRNA in males (P Ͻ 0.05). Map2k1 expression was not different at E17.5 (Fig. 5D) . MAPK1, MAPK3, and total MAPK protein expression was not changed by Cort exposure in either sex at E14.5 (data not shown).
Placental compartment volumes
Because Cort exposure increased the weight of placentas from fetuses at E17.5 only, placentas from male and female fetuses from this age group were selected to perform extensive stereology to calculate whole placental volume, junctional zone volume, and labyrinth volume. Whole placental volume (Fig. 6A) was not significantly affected by Cort exposure in placentas from male or female fetuses. However, the absolute junctional zone volume was significantly increased by 24% in placentas from male (Untr, 0.031 Ϯ 0.002 cm 3 ; Cort, 0.039 Ϯ 0.002 cm 3 ; P Ͻ 0.05) but not female (Untr, 0.037 Ϯ 0.003 cm 3 ; Cort, 0.035 Ϯ 0.005 cm 3 ) fetuses prenatally exposed to Cort, whereas the absolute labyrinth volume was not changed in either sex (data not shown). The proportion of the placenta that is labyrinth was therefore significantly smaller in Cortexposed placentas from male but not female fetuses (P Ͻ 0.05, Fig. 6B ), and the percentage of placenta that is junctional zone was increased in placentas from male but not female Cort-exposed fetuses (P Ͻ 0.05, Fig. 6C ).
Discussion
The current study demonstrates that increased maternal Cort exposure can alter normal placental growth and de- (21) reported in the rat that the currently used dose of 33 g/kg⅐h (or approximately 0.8 mg/kg⅐d) increased plasma Cort levels approximately 3-fold, whereas cortisol administration to sheep (5 mg/h) increased levels approximately 8-fold above basal level (22) . This magnitude of increase suggests these doses produce maternal levels in the high physiological range. The current model used osmotic pumps to provide a constant infusion of Cort for 60 h from E12.5. The timing of exposure we have selected coincides with a period of maximal growth and proliferation of the definitive murine placenta and was chosen for this reason. In our murine model, maternal plasma Cort levels increased approximately 3-fold, which is a similar magnitude of change as reported in the rat (21) . In addition, the observed levels are similar to those reported in late pregnancy in the mouse (23) . In the dam, Cort exposure also reduced mRNA levels of genes involved in adrenal steroidogenesis, shown previously to be down-regulated in response to ACTH or GC exposure (18, 19) . The approximate 50% reduction in both Cyp11b1 and Star mRNA levels indicates that although the dose of Cort was sufficiently high as to decrease the expression of these genes, steroidogenic mRNA expression was not completely suppressed as may be the case at pharmacological doses of dexamethasone (20) .
Placental and fetal growth
Although our model of Cort exposure did not impair fetal growth at the times examined, placental growth and Endocrinology, November 2012, 153(11):5500 -5511 endo.endojournals.orgdevelopment were significantly affected. Cort exposure in our study did not directly affect placental weight after 48 h (E14.5); however, 60 h after completion of Cort exposure (E17.5), absolute placental weight, placental wet weight, and the placenta to body weight ratio were increased. This increase in placental size has likewise been seen in other animal models of programming (24) . Placental weight alone and in relation to birth weight have been shown in the human to be predictors of adult health (reviewed in Ref. 25) . This relationship has been shown to fit a Ushaped curve with individuals born with very low or very high placenta to body weight ratios being more prone to adult disease than those who were born with placentas of appropriate size for their birth weight (26) . Martyn et al. (26) has shown that standard mortality ratios for coronary heart disease were highest for individuals who had a placental weight as a ratio of body weight higher than 21.5% or lower than 15%, suggesting a relatively narrow window of optimal placental size. Furthermore, this increase in placental size at E17.5 was most evident in placentas taken from male fetuses. Cort exposure did not affect stereological measurements of placental volume, compartment volume, or relative compartment volume in placentas from female fetuses. In placentas from male fetuses, although overall placental volume was not different, we found a 24% increase in absolute junctional zone volume and an 18% increase in the percentage of junctional zone volume contributing to whole placenta volume. This was associated with a 17% decrease in labyrinth as a total of placental volume. This increase in junctional zone volume without any overt increase in whole placental volume may account for the observed increase in whole placental weight. By its nature, the junctional zone is very cellular in structure, in contrast to the very vascular labyrinth zone. As such, the junctional zone may weigh more per cubic centimeter of tissue compared with the labyrinth zone that would have a weight dependent on placental blood volume, which may to some extent be lost at the time of collection.
In addition to changes in placental weight and volume, placental shape has been affected by Cort exposure. We found placental length was greater in those animals exposed to Cort at E14.5 despite no apparent increase in placental weight. An increase in the placental length would result in an increased ovality of the placenta, which has been shown to be associated with an increased incidence of adult disease (27) (28) (29) . We also found an increase in placental depth (or thickness) at both E14.5 and E17.5. Increased placental thickness has been shown to be asso-
FIG. 4. Effects of maternal Cort exposure (black bars)
on Kdr gene expression in placentas from male and female fetuses at E14.5 (A) and E17.5 (B), Vegfa gene expression at E14.5 (C) and E17.5 (D), and VEGFA protein expression at E14.5 (E and G) and E17.5 (F and H) compared with Untr controls (white bars). Data are represented as litter means of sexed animals Ϯ SEM. Gene expression: *, P Ͻ 0.05 for Bonferroni post hoc compared with Untr of same sex; n ϭ 8 -12 placentas from five to seven litters per group. Protein expression: *, P Ͻ 0.05 by unpaired t test comparing Untr and Cort of same sex; n ϭ 6 from five to six litters per group.
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ciated with preeclampsia (30) . Famine during pregnancy has been shown to either increase or decrease placental thickness depending on the timing of the insult as well as the sex of the fetus (31) . The increase in placental thickness, especially at E17.5, may be related to the overall changes in placental size and in the males may be due to the increase in junctional zone without a decrease in labyrinth. Collectively, our data suggest short-term Cort exposure can alter placental shape, which fits with the current human epidemiological data and may predict long-term poor health in offspring. Perhaps surprisingly, unlike most of the previous morphological data, Cort-induced changes to placental dimensions were not sex specific, suggesting that although placentas from males were more affected by Cort, the placentas from females were also altered to some degree. Cort exposure did not significantly affect fetal weight at either E14.5 or E17.5. Similar models of Cort exposure in the rat (21) have likewise seen no change in fetal weight during or after Cort exposure. We have previously reported that dexamethasone exposure, given over the same gestational period, reduces fetal weight at E14.5 in association with a reduction in placental weight in females only (13) . Dexamethasone also reduced whole placental and junctional zone cross-sectional area at E14.5 in females only (13) . Although this study used a Cort concentration approximately equipotent to the dexamethasone previously used, clear differences between the two GC were observed. Dexamethasone exposure seems to have had a more direct but transient influence on fetal growth in both males and females and seems to have predominantly affected placentas from female fetuses. In contrast, Cort has not directly influenced fetal size at either E14.5 or E17.5; however, the disruption in placental development may ultimately lead to a long-term disruption in fetal growth as our preliminary data suggest weight at birth is reduced in our model of Cort exposure (Moritz, K. M., unpublished data).
Placental GR and placental barrier
The current study has shown that, in response to Cort, Nr3c1 (Gr) is increased in males not only during treatment but also long after the completion of exposure. Thus, Cort has acted on the placental GR and induced positive feedback to further up-regulate its own expression both immediately and in the long term. This increased Gr expression may result in increased GC-GR signaling immediately from the increased exogenous Cort and also later on in pregnancy due to an overall increased sensitivity to the high levels of naturally circulating Cort present later in pregnancy. Although in many adult tissues, GC exposure reduces GR expression (32) , animal models have shown exposure of feto-placental tissues to GC to increase GR expression, notably within the liver, pituitary, and limbic structures of the fetus (33) (34) (35) and the placenta (36) . Furthermore, McCabe et al. (35) showed a GC-induced increase in GR expression within the fetal limbic system in males but not females. This Cort-induced up-regulation of the Gr mRNA in males only is of great interest in that it may explain some of the sex differences observed in this study, although it should be noted that we were unable to optimize a GR antibody so could not confirm an increase in protein levels. It is also interesting to note that, in contrast, we have reported previously that dexamethasone does not affect Nr3c1 mRNA levels in placentas of either sex (13) .
We have previously shown using a similar protocol that maternal dexamethasone exposure increases Hsd11b2 mRNA and protein in placentas from females at E14.5 (13) . In this study, we have shown that Hsd11b2 mRNA expression is initially fortified during Cort exposure in placentas of both sexes but 11␤-HSD2 protein levels were statistically increased only in placentas from female fetuses (38%). In males, protein levels increased slightly (19%), but this increase was not significant. It has been reported previously that Hsd11b2 is regulated at both the transcriptional and translational level in response to cellular stress (37) , and it is thus unsurprising, given that we see a greater increase in mRNA levels in females compared with males, that the increase in protein expression was significant only in placentas from females. This temporary increase in the expression levels of the GC barrier may provide a significant amount of protection particularly to female fetuses during the period of exposure. On the other hand, the maintained increase in Gr expression at E17.5 in placentas from male fetuses may make male fetuses particularly vulnerable to GC effects due to the increasing endogenous Cort levels, which as noted above, occur later in pregnancy (38) .
Growth factors
Of the growth factors, receptors, and signaling molecules studied, Cort-induced changes occurred in placentas of males only. Placental mRNA levels of Vegfa and its predominant receptor Kdr were both up-regulated in Cort-exposed males at E14.5, followed by decreased levels of Vegfa mRNA at E17.5, 60 h after the cessation of Cort treatment. Interestingly, VEGFA protein expression did not match this gene expression pattern. Others have also noted similar differences in Vegfa gene and protein expression (11), and we have previously reported differences in gene and protein expression of placental Vegfa in response to dexamethasone (13) . One possible explanation for this discrepancy could be simply that we are observing a time delay in the progression from RNA transcription to protein translation. Thus, the increase in Vegfa mRNA levels at E14.5 may translate to the increase in protein at E17.5, at which point the effects of Cort on Vegfa mRNA expression have ceased. Following this rationale, an initial down-regulation of Vegfa mRNA expression at the beginning of Cort exposure, not seen by our chosen gesta- (42) . Whatever the mechanism, our data suggest a disruption in VEGFA protein levels in males, which may have an impact on continued vascularization within the placenta. This would be of interest to examine in future studies. Placental Igf2 is important for regulating placental and fetal growth, with changes in expression being reflected in changes to placental and fetal size (43) . Placental Igf2 expression levels have been shown previously to be altered in response to maternal dexamethasone exposure in the rat (10) . In our study, Cort increased Igf2 expression at E14.5 in placentas from males, but levels were decreased by E17.5 after Cort withdrawal. Igf2 plays an important role in placental growth most notably within the junctional zone (44) . The increase in Igf2 in E14.5 males may underlie the mechanisms involved in the increased weight and junctional zone seen at E17.5 in the placentas from males. Finally, we demonstrated Cort-induced increases Map2k1 mRNA levels at E14.5 in placentas from male fetuses. Map2k1 is known to be important in the signaling involved in placental growth and development (45) , and other growth factors, including Igf2, are known to signal through this cascade (46) . MAP2K1 acts to phosphorylate MAPK1 and MAPK3 and induce further downstream signaling. Although we have not reported any change in MAPK protein expression, MAPK phosphorylation should be examined in future studies to further elucidate the role of this cascade in Cort-induced alterations in placental growth. Collectively, these changes in growth and signaling factors may explain the changes in weight and morphology of the placentas from male fetuses exposed to Cort. These Cort-induced changes to growth factor expression are in contrast to our previous studies using dexamethasone, which did not affect Igf2 expression and reduced MAPK levels in females only (13) ; however, the changes in expression levels in both the current and previous study fit the observed changes in placental growth.
Conclusion
Our findings show that maternal Cort exposure during pregnancy can alter murine placental weight and structural composition in males without any overt changes in fetal weight, whereas females appear largely unaffected. Of particular interest is that this study has identified male vulnerability to Cort exposure at the level of the placenta. This has been shown to be associated with altered gene and protein expression of important placental growth factors. In turn, this altered placental development may impair fetal development and program adult disease. The 60-h period of Cort exposure seems to have not only affected placental growth but also altered the factors responsible for determining how the placenta responds to future insults. As such, women who have experienced a period of stress during pregnancy may have altered placental development, particularly if they are carrying male fetuses. In turn, offspring may be at risk of developing programmed adult disease. Furthermore, we speculate that women who have experienced stress during midpregnancy may have developed an altered placental responsiveness to future GC exposure, such as additional stressful stimuli or synthetic GC administration.
